Keywords
hyperlipidemia
polymorphism of the SLCO1B1 gene
How to Cite
Abstract
It was studied the prevalence of polymorphism of the SLCO1B1 gene in patients multiprofile medical center of University clinic № 1. As a result of the study, there were identified 70 (55.1%) carriers of the "wild" type c.521TT; 47 (37%) genotype c.5221T and 10 (7.9%) of patients with homozygous (c.521CS) carriage of the allelic variant of SLCO1B1. An algorithm has been developed for individual selection of the maximum dose of statin and recommended for practical use by experts of the European Science Foundation.References
Buhaienko V.V. (2014). Statiny v pervichnoi i vtorichnoi profilaktike serdechno-sosudistogo riska: novyi vzgliad na staruiu problemu [Statins in primary and secondary prevention of cardiovascular risk: a new look at the old problem]. Ukrainskii kardoil. Zhurnal – Ukrainian cardiologist magazine. 3: 103–108. [in Russian].
Khokhlov A.A., Sychev D.A., Sirotkina A.M. (2016). Aspekty bezopasnoho primeneniia statinov: mezhlekarstvennoie vzaimodeistviie, farmakoheneticheskiie voprosy [Aspects of safe use of statins: inter-drug interactions, pharmacogenetic issues]. Universum: Meditsina i farmakologiia: electron. nauchn. zhurn. – Universum: Medicine and Pharmacology: electron. scientific. journal. 1–2 (24). URL: http://7universum.com/ru/med/archive/item/2950 [in Russian].
Banach M., Rizzo M., P.P. Toth, M. Farnier, M.H. Davidson, K. Al-Rasadi et al. (2015). Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch. Med. Sci. 11 (1): 1–23.
Voora D., Shah S.H., Spasojevic I., Ali S., C.R. Reed, B.A. Salisbury et al. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54 (17): 1609–1616.
Kazakov R.E., Yevteev V.A., Muslimova O.V., Muslimova O.V., Mazerkina I.A. (2016). Znacheniie heneticheskikh faktorov v prohnozirovanii pobochnykh deistvii statinov [The importance of genetic factors in predicting the side effects of statins]. Mezhdunarodnyi zhurnal prikladnykh i fundamentalnych issledovanii – International Journal of Applied and Fundamental Research. 8: 691–698 [in Russian].
Shuev H.N., Sychev D.A., Hrachev A.V. (2015). Polimorfizm hena SLCO1B1, assotsiirovannyi s razvitiem statin-indutsirovaanoi miopatii, uroven vitamina D u rossiiskikh patsientov s hiperlipidemiiami [Polymorphism of the SLCO1B1 gene associated with the development of statin-induced myopathy, the level of vitamin D in Russian patients with hyperlipidemia] Kreativnaia kardiolohiia – Creative cardiology. 4: 40–45.
Bays H. (2006). Statinsafety: an over view and assessment of the data. Am. J. Cardiol. 97 (8A): 6–26.
Carr D.F., O’Meara H., Jorgensen A.L., Campbell J., Hobbs M., McCann G. et al. (2013). SLCO1B1 Genetic variant associated with statin-induced myopathy: A proof-of concept study using the clinical practice research datalink. Clinical Pharmacology & Therapeutics. 94 (6): 695–670.
FDa expands advice on statin Risks http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCm293705.pdf
Linde R., Peng L., Desai M., Feldman D. (2010). The role of vitamin D and SLCO1B1·5 gene polymorphism in statin-associated myalgias. Dermatoendocrinology. 2 (2): 77–84.
Seredenin S.B. (2004). Lektsii po farmakohenetike [Lectures on pharmacogenetics]. Moskow: MIA. 303 pp.[in Russian].
Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Electronic resource: http: // www.fda.gov/downloads/ gs/guidancecomplianceregulatoryinformation/guidances/ ucm337169.pdf
Tirona R.G., Leake B.F., Merino G., Kim R.B. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European and African-Americans. The Journal of Biological Chemistry. 276 (38): 35669–35675.
Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F. et al. (2008). SLCO1B1 variants and statin-induced myopathy a genomewide study. New Engl. J. Med. 359 (8): 789–799.
Sirotkina A.M., Khokhlov A.L., Voronina Ye.A., Mohutov M.S., Driazhenkova I.V., Tzariova I.N. et al. (2013). Rasprostranennost polimorfnoho markera hena SLCO1B1 u patsientov s dislipidemiiei I sistemnym aterosklerosom [Prevalence of the polymorphic marker of the gene in patients with dyslipidemia and systemic atherosclerosis]. Kardiovaskuliarnaia terapiia i profilaktika – Cardiovascular therapy and prevention. 12 (april). Spetsialnyi vypusk. 22 [in Russian].
Kukes B.H. (Eds.). (2009). Klinicheskaia farmakolohiia: uchebnik dlia vuzov [Clinical pharmacology: a textbook for universities]. (4 ed.). 1056 pp. [In Russian].
Sortica V.A., Fiegenbaum M., Lima L.O,. Van der Sand C.R., Van der Sand L.C., Ferreira M.E. et al (2012). SLCO1B1 gene variability influences lipid-lowering efficacy on silvastatin therapy in Southern Brazilians. Clin. Chem. Lab. Med. 50 (3): 441.
Becquemont L., Alfirevic A., Amstutz U., Brauch H., Jacqz-Aigrain E., Laurent-Puig P. et al. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB. Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. № 12 (1): 113–124.